By Fineline Cube 
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced an agreement with the National Natural Science Foundation of China (NSFC) to establish the “NSFC-Private Enterprise Innovation Development Joint Fund.” This initiative marks a significant step in fostering innovation and research in China’s pharmaceutical sector.
Funding Commitment
Hengrui has committed RMB 120 million (USD 17 million) from 2025 to 2027, with the NSFC providing RMB 12 million (USD 1.7 million) at a 1:10 ratio. This substantial investment highlights the company’s dedication to advancing scientific research and innovation.
Research Focus Areas
The joint fund aims to attract and gather outstanding researchers from across the country to address the urgent needs of enterprise development. The research will focus on key areas such as oncology, metabolic diseases, immune diseases, anesthesia and critical care medicine, and clinical pharmacy. This collaborative effort is expected to drive significant advancements in these critical fields.-Fineline Info & Tech